BC Innovations | Feb 5, 2019
Distillery Therapeutics

Cancer

INDICATION: Renal cancer In vitro and cell culture studies identified an aminothiazole-based negative allosteric modulator (NAM) of CSNK2 that could help treat renal cell carcinoma (RCC). Chemical synthesis and in vitro testing of aminothiazole analogs...
BC Innovations | Aug 17, 2017
Translation in Brief

Stopping the invasion

A team from the Netherlands Cancer Institute (NKI) has identified a network of extracellular matrix proteins that drives glioblastoma invasiveness and a master switch -- interferon regulatory factor 3 (IRF3) -- that can turn it...
BC Innovations | Aug 16, 2017
Distillery Therapeutics

Cancer

INDICATION: Brain cancer Cell culture studies suggest activating IRF3 or inhibiting its negative regulator CSNK2 could help treat glioblastoma multiforme (GBM). In mouse brain slices co-cultured with a patient-derived GBM cell line, vector-mediated constitutively active...
BC Extra | Dec 14, 2013
Financial News

Senhwa raises $17 million in series B

Cancer company Senhwa Biosciences Inc. (New Taipei City, Taiwan) raised $17 million in a series B round from existing and new investors including H&Q Asia Pacific; Morningside; and China Investment & Development. Senhwa's CX-5461 , a...
BC Week In Review | Apr 23, 2012
Clinical News

Cylene Pharmaceuticals preclinical data

In a mouse xenograft model of cancer, CX-8184 showed "potent" antitumor activity and was well tolerated. Additionally, the second-generation oral protein kinase CK2 inhibitor demonstrated broad anti-proliferative activity against a panel of 32 cancer cell...
BC Week In Review | Jun 20, 2011
Clinical News

CX-4945: Phase I data

An open-label, dose-escalation, U.S. Phase I trial in 27 patients showed that oral CX-4945 produced 6 cases of stable disease. The MTD was twice-daily 1,000 mg CX-4945 given for the first 3 consecutive weeks of...
BC Week In Review | Jun 20, 2011
Clinical News

CX-4945: Phase I data

An open-label, dose-escalation, U.S. Phase I trial in 17 patients showed that oral CX-4945 produced 3 cases of stable disease. The MTD was 600 mg CX-4945 given 4 times daily for the first 3 consecutive...
BC Week In Review | Oct 25, 2010
Company News

Cylene Pharmaceuticals, Horizon Discovery Ltd. deal

Cylene will use Horizon's X-MAN panel of over 250 genetically-defined human cancer cell lines to identify patients who will respond best to Cylene's oral protein kinase CK2 inhibitor, CX-4945 , in an upcoming Phase II trial...
BC Week In Review | Sep 27, 2010
Clinical News

CX-4945: Phase I started

Cylene began an open-label, dose-escalation, U.S. Phase I trial to evaluate oral CX-4945 given 4 times daily for the first 21 days of a 28-day cycle in 20 patients with relapsed or refractory MM. Cylene...
BC Extra | Sep 24, 2010
Financial News

Existing investors top off Cylene's C round

Cylene Pharmaceuticals Inc. (San Diego, Calif.) raised $12 million in an extension of a series C round, bringing the total raised in the round to $56 million. Existing investors Sanderling Ventures; HBM BioVentures; Novartis BioVenture...
Items per page:
1 - 10 of 14